+44 7868 792050
Pedro Cuevas, Miguel Hinojosa, Javier Angulo and Guillermo Giménez-Gallego
Allergic rhinitis is a common condition that causes a negative effect on patient well-being. Antihistamines and glucocorticoids, the first line treatments usually administered for rhinitis, are normally associated to side effects. In addition, they may show limited efficiency in controlling nasal obstruction, edema and hyperemia occurring secondary to persistent inflammation. Dobesilate, an inhibitor of fibroblast growth factor and vascular endothelial growth factor, shows a markedly anti-inflammatory activity in several inflammation-dependent diseases and inflammation models. Our study shows that nostril spray application of dobesilate for one week is effective in reducing symptoms and signs in patients with seasonal allergic rhinitis.